United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction on Wednesday, June 3rd. The stock was sold at an average price of $547.61, for a total value of $5,202,295.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at approximately $22,185,323.93. This represents a 19.00% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

United Therapeutics Stock Performance

United Therapeutics stock opened at $547.69 on Friday. The firm has a market cap of $23.25 billion, a P/E ratio of 20.22, a P/E/G ratio of 1.78 and a beta of 0.57. The business’s fifty day moving average is $568.06 and its two-hundred day moving average is $518.61. United Therapeutics Corporation has a 52 week low of $272.12 and a 52 week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The business had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. United Therapeutics had a return on equity of 19.24% and a net margin of 40.62%.United Therapeutics’s revenue for the quarter was down 1.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $6.63 EPS. On average, equities research analysts predict that United Therapeutics Corporation will post 26.92 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on UTHR. Bank of America boosted their target price on United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research report on Tuesday, March 31st. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their target price for the stock from $575.00 to $735.00 in a research report on Thursday, May 7th. Oppenheimer boosted their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a research report on Thursday, February 26th. Raymond James Financial began coverage on United Therapeutics in a research report on Friday, April 10th. They set an “outperform” rating and a $700.00 target price for the company. Finally, UBS Group boosted their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Eleven equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $619.42.

Institutional Investors Weigh In On United Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Optimize Financial Inc bought a new stake in United Therapeutics in the third quarter valued at about $444,000. Leuthold Group LLC increased its holdings in United Therapeutics by 41.4% in the fourth quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock valued at $5,200,000 after purchasing an additional 3,126 shares during the last quarter. Tobam increased its holdings in United Therapeutics by 183.9% in the third quarter. Tobam now owns 7,646 shares of the biotechnology company’s stock valued at $3,205,000 after purchasing an additional 4,953 shares during the last quarter. UBS Group AG increased its holdings in United Therapeutics by 45.3% in the fourth quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock valued at $110,045,000 after purchasing an additional 70,445 shares during the last quarter. Finally, Perpetual Ltd bought a new stake in United Therapeutics in the fourth quarter valued at about $1,059,000. Institutional investors own 94.08% of the company’s stock.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.